CellReady: Our roots in Cell Therapy
Cell Easy’s story is rooted in the heart of cell therapy research, and this invaluable experience shapes every action we take to help you bring life-saving treatments forward.
800.109
Cells per tissue donation
3,5.109
Cells per batch
25
Analytical parameters screened
Our Origins
Our journey began with early clinical Mesenchymal Stem Cell (MSC) programs at the French Blood Establishment (EFS). Cell-Easy licensed an innovative large-scale culture process for Adipose-Derived Stem Cells (ASCs) on adherent surfaces.
ASCs are remarkable cells, recognized for their natural ability to regenerate tissue, modulate immune responses, and support repair processes. While early autologous trials demonstrated their potential, treating one patient at a time was neither sustainable nor scalable. To efficiently reach more patients, we transformed the autologous process into an allogeneic one and created CellReady, our proprietary GMP-grade allogeneic ASC platform. This platform enables us to expand cells from a single healthy donor under controlled conditions, producing thousands of clinical doses for patients.
Benefits of CellReady:
- Expand cells from a single healthy donor
- Produce multiple clinical doses for multiple patients
- Fully xeno-free, reproducible, scalable, and GMP-compliant manufacturing process
Every step has been continuously refined to ensure clinical translatability and reliable performance.
Clinical Programs using CellReady
In collaboration with CHU Toulouse, our Adipose derived MSCs are applied across five clinical programs:
| Program Name | Indication | Clinical Phase |
| A3D | Alzheimer’s disease | Phase 1 (First-in-Human) |
| AlloFist | Crohn’s disease with perianal fistulas | Phase 1/2 |
| ADUSE | Systemic sclerosis — ischemic digital ulcers & possibly oral ulcers | Phase 2 |
| AMUSE | Oral ulcers associated with systemic sclerosis | Phase 1 |
| AlloDream | Peripheral limb ischemia | Phase 1 |
MSC Expertise & Ready-to-Use Cells
We provide adipose-derived MSCs (RUO and GMP) together with end-to-end expertise to support industrial-scale manufacturing, preclinical development, and clinical translation. Donor qualification and characterization ensure safety, reproducibility, and robust biological performance. We also generate extensive preclinical data, including toxicity and tumorigenicity studies in relevant mouse models, and perform an in-depth analytical assessment covering safety, identity, and potency across more than 25 critical parameters.
We deliver customized GMP batches to enable rapid access to industrial quantities of MSCs, suitable for downstream uses such as engineered or native drug products, starting or intermediate cell banks, exosome production, or cellular cargo and meatable applications.
Discover more about Cell Easy
Cell Easy
News
Let’s talk about your project
Let’s turn your vision into a reality.
Phone: +33 534 276 550
Address: Cell-Easy SAS, 4 bis avenue Hubert Curien,
31100 Toulouse, France
Mail: info@cell-easy.com